MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board


Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Aim(s): The present study investigates the opportunity of a MBTT in NEN cell lines.

Materials and methods: Using our newly established panel of 4 NET (NT-3, NT-18P, NT-18LM, NT-36) and 2 NEC (NT-32, NT-38) cell lines, a targeted exome sequencing of a 700 cancer gene panel was performed. After identification of potential therapeutic targets, cell lines were treated with specific inhibitors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

To read the full abstract, please log into your ENETS Member account.